CA2253934A1 - Inhibiteurs de farnesyltransferase de proteines - Google Patents
Inhibiteurs de farnesyltransferase de proteines Download PDFInfo
- Publication number
- CA2253934A1 CA2253934A1 CA002253934A CA2253934A CA2253934A1 CA 2253934 A1 CA2253934 A1 CA 2253934A1 CA 002253934 A CA002253934 A CA 002253934A CA 2253934 A CA2253934 A CA 2253934A CA 2253934 A1 CA2253934 A1 CA 2253934A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- phenyl
- imidazole
- carbamoyl
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Cette invention concerne de nouveaux inhibiteurs d'enzymes du type farnésyltransférase de protéines, ainsi que des procédés de préparations de ces inhibiteurs et des compositions les contenant. Ces inhibiteurs sont utiles dans le traitement du cancer, de la resténose, du psoriasis, de l'endométriose, de l'athérosclérose ou, encore, d'infections virales.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1611096P | 1996-05-22 | 1996-05-22 | |
US60/016,110 | 1996-05-22 | ||
US3366296P | 1996-12-17 | 1996-12-17 | |
US60/033,662 | 1996-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2253934A1 true CA2253934A1 (fr) | 1997-11-27 |
Family
ID=26688183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002253934A Abandoned CA2253934A1 (fr) | 1996-05-22 | 1997-04-29 | Inhibiteurs de farnesyltransferase de proteines |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0938494A1 (fr) |
JP (1) | JP2000511527A (fr) |
CN (1) | CN1219174A (fr) |
AU (1) | AU728477B2 (fr) |
BG (1) | BG102936A (fr) |
BR (1) | BR9709354A (fr) |
CA (1) | CA2253934A1 (fr) |
CO (1) | CO4960642A1 (fr) |
CZ (1) | CZ376498A3 (fr) |
EA (1) | EA199801031A1 (fr) |
EE (1) | EE9800408A (fr) |
GE (1) | GEP20012500B (fr) |
IL (1) | IL126833A0 (fr) |
NO (1) | NO985405L (fr) |
NZ (1) | NZ332712A (fr) |
PL (1) | PL330120A1 (fr) |
SK (1) | SK161098A3 (fr) |
WO (1) | WO1997044350A1 (fr) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981562A (en) * | 1996-01-30 | 1999-11-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997027854A1 (fr) * | 1996-01-30 | 1997-08-07 | Merck & Co., Inc. | Inhibiteurs de la farnesyl-proteine transferase |
EP0944387A1 (fr) * | 1996-01-30 | 1999-09-29 | Merck & Co., Inc. | Inhibiteurs de la farnesyle transferase |
US5968965A (en) * | 1996-01-30 | 1999-10-19 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6028201A (en) * | 1996-01-30 | 2000-02-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6300501B1 (en) | 1996-05-22 | 2001-10-09 | Warner-Lambert Company | Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase |
WO1998046625A1 (fr) * | 1997-04-11 | 1998-10-22 | Warner-Lambert Company | Inhibiteurs dipeptidiques de la farnesyltransferase |
US6737410B1 (en) | 1997-04-11 | 2004-05-18 | Warner-Lambert Company | Inhibitors of protein farnesyl transferase |
US20030069231A1 (en) | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
US6369034B1 (en) * | 1998-04-27 | 2002-04-09 | Warner-Lambert Company | Functionalized alkyl and alenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors |
US6284755B1 (en) | 1998-12-08 | 2001-09-04 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
AU2478500A (en) | 1998-12-08 | 2000-06-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
WO2001051494A1 (fr) | 2000-01-12 | 2001-07-19 | Merck & Co., Inc. | Inhibiteurs de prenyle-proteine transferase |
JP2002188646A (ja) * | 2000-12-20 | 2002-07-05 | Nsk Ltd | 転がり軸受及び軸受装置 |
US7595312B2 (en) | 2002-10-25 | 2009-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
WO2005049589A2 (fr) * | 2003-10-14 | 2005-06-02 | Cadila Healthcare Limited | Nouveaux composes heterocycliques |
DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
ES2382814T3 (es) | 2005-05-17 | 2012-06-13 | Merck Sharp & Dohme Ltd. | Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
EP2946778A1 (fr) | 2006-09-22 | 2015-11-25 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de la synthèse d'acides gras |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
KR101591656B1 (ko) | 2007-01-10 | 2016-02-19 | 엠에스디 이탈리아 에스.알.엘. | 폴리(adp-리보오스) 폴리머라아제(parp) 억제제로서의 아미드 치환된 인다졸 |
AU2008221263B2 (en) | 2007-03-01 | 2012-02-23 | Novartis Ag | Pim kinase inhibitors and methods of their use |
EP2152700B1 (fr) | 2007-05-21 | 2013-12-11 | Novartis AG | Inhibiteurs du csf-1r, compositions et procédés d'utilisation |
WO2009002495A1 (fr) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase |
EP2413932A4 (fr) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | Inhibiteurs de l'activité akt |
CN102480966B (zh) | 2009-06-12 | 2015-09-16 | 达娜-法勃肿瘤研究所公司 | 融合的杂环化合物及其用途 |
EP2488028B1 (fr) | 2009-10-14 | 2020-08-19 | Merck Sharp & Dohme Corp. | Pipéridines substituées qui accroissent l'activité de p53 et utilisations de ces composés |
EP2937345B1 (fr) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de la kinase raf de type ii |
EP2547661A2 (fr) | 2010-03-16 | 2013-01-23 | Dana-Farber Cancer Institute, Inc. | Composés d'indazole et leurs utilisations |
EP2584903B1 (fr) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk |
WO2012018754A2 (fr) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian) |
AU2011292261B2 (en) | 2010-08-17 | 2015-05-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) |
WO2012027236A1 (fr) | 2010-08-23 | 2012-03-01 | Schering Corporation | Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor |
US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
ES2663009T3 (es) | 2010-10-29 | 2018-04-10 | Sirna Therapeutics, Inc. | Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic) |
WO2012087772A1 (fr) | 2010-12-21 | 2012-06-28 | Schering Corporation | Dérivés d'indazole utiles en tant qu'inhibiteurs de erk |
EP2699568A1 (fr) | 2011-04-21 | 2014-02-26 | Piramal Enterprises Limited | Forme cristalline d'un sel d'un dérivé de morpholinosulfonylindole et son procédé de préparation |
EP2770987B1 (fr) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Nouveaux composés qui sont des inhibiteurs d'erk |
AU2012340200B2 (en) | 2011-11-17 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-Terminal Kinase (JNK) |
WO2013165816A2 (fr) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | Compositions de petit acide nucléique interférent (sina) |
WO2014052563A2 (fr) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Nouveaux composés inhibiteurs de erk |
WO2014063068A1 (fr) | 2012-10-18 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de cycline-dépendante kinase 7 (cdk7) |
WO2014063054A1 (fr) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations |
US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
CA2892361A1 (fr) | 2012-11-28 | 2014-06-05 | Merck Sharp & Dohme Corp. | Utilisation d'un inhibiteur wee1 pour traiter un cancer caracterise par de faibles niveaux d'expression de proteines tyrosine et threonine kinases 1 (pkmyt1) associee a la membrane |
AU2013361694B2 (en) | 2012-12-20 | 2017-10-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
WO2014120748A1 (fr) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2 |
WO2015034925A1 (fr) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Polynucléotides circulaires |
CN105849099B (zh) | 2013-10-18 | 2020-01-17 | 达纳-法伯癌症研究所股份有限公司 | 周期蛋白依赖性激酶7(cdk7)的多环抑制剂 |
EP3057955B1 (fr) | 2013-10-18 | 2018-04-11 | Syros Pharmaceuticals, Inc. | Composes heteroaromatiques utiles dans le traitement de maladies proliferatives |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
EP3347018B1 (fr) | 2015-09-09 | 2021-09-01 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinases cycline-dépendantes |
JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
SG11201908813QA (en) | 2017-04-13 | 2019-10-30 | Aduro Biotech Holdings Europe B V | Anti-sirp alpha antibodies |
EP3706742B1 (fr) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Inhibiteurs de prmt5 |
WO2019148412A1 (fr) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anticorps bispécifiques anti-pd-1/lag3 |
WO2020033282A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5352705A (en) * | 1992-06-26 | 1994-10-04 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
WO1995009001A1 (fr) * | 1993-09-30 | 1995-04-06 | Merck & Co., Inc. | Inhibiteurs de farnesyl-proteine transferase |
JP3597863B2 (ja) * | 1993-11-05 | 2004-12-08 | ワーナー−ランバート・コンパニー | タンパク質:ファルネシルトランスフェラーゼの置換されたジ‐およびトリペプチド阻害剤 |
US5571792A (en) * | 1994-06-30 | 1996-11-05 | Warner-Lambert Company | Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase |
-
1997
- 1997-04-29 EA EA199801031A patent/EA199801031A1/ru unknown
- 1997-04-29 CZ CZ983764A patent/CZ376498A3/cs unknown
- 1997-04-29 WO PCT/US1997/006591 patent/WO1997044350A1/fr not_active Application Discontinuation
- 1997-04-29 BR BR9709354A patent/BR9709354A/pt not_active Application Discontinuation
- 1997-04-29 EE EE9800408A patent/EE9800408A/xx unknown
- 1997-04-29 SK SK1610-98A patent/SK161098A3/sk unknown
- 1997-04-29 IL IL12683397A patent/IL126833A0/xx unknown
- 1997-04-29 CN CN97194835A patent/CN1219174A/zh active Pending
- 1997-04-29 PL PL97330120A patent/PL330120A1/xx unknown
- 1997-04-29 JP JP09542369A patent/JP2000511527A/ja not_active Abandoned
- 1997-04-29 EP EP97922365A patent/EP0938494A1/fr not_active Withdrawn
- 1997-04-29 GE GEAP19974612A patent/GEP20012500B/en unknown
- 1997-04-29 AU AU28058/97A patent/AU728477B2/en not_active Ceased
- 1997-04-29 CA CA002253934A patent/CA2253934A1/fr not_active Abandoned
- 1997-04-29 NZ NZ332712A patent/NZ332712A/xx unknown
- 1997-05-26 CO CO97028769A patent/CO4960642A1/es unknown
-
1998
- 1998-11-19 BG BG102936A patent/BG102936A/bg unknown
- 1998-11-20 NO NO985405A patent/NO985405L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
GEP20012500B (en) | 2001-07-25 |
CN1219174A (zh) | 1999-06-09 |
EP0938494A1 (fr) | 1999-09-01 |
BR9709354A (pt) | 1999-08-10 |
EE9800408A (et) | 1999-06-15 |
CO4960642A1 (es) | 2000-09-25 |
EA199801031A1 (ru) | 1999-06-24 |
IL126833A0 (en) | 1999-08-17 |
NO985405D0 (no) | 1998-11-20 |
AU2805897A (en) | 1997-12-09 |
AU728477B2 (en) | 2001-01-11 |
CZ376498A3 (cs) | 1999-02-17 |
JP2000511527A (ja) | 2000-09-05 |
NZ332712A (en) | 2000-07-28 |
WO1997044350A1 (fr) | 1997-11-27 |
NO985405L (no) | 1999-01-19 |
PL330120A1 (en) | 1999-04-26 |
SK161098A3 (en) | 2000-06-12 |
BG102936A (bg) | 1999-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2253934A1 (fr) | Inhibiteurs de farnesyltransferase de proteines | |
US6300501B1 (en) | Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase | |
EP1076663B1 (fr) | Derives fonctionnalises de glycinamides, a chaine laterale alkyle et alcenyle, utilises comme inhibiteurs de la farnesyl-transferase | |
JP2001512135A (ja) | Vla−4によって媒介された白血球接着を阻害するジペプチドおよび関連化合物 | |
US5574016A (en) | Peptide compound and a process for the preparation thereof | |
US5827866A (en) | Peptidyl heterocycles useful in the treatment of thrombin related disorders | |
US5827860A (en) | Peptidyl heterocycles useful in the treatment of thrombin related disorders | |
US6265382B1 (en) | Dipeptide inhibitors of protein farnesyltransferase | |
AU758891B2 (en) | Combinations of protein farnesyltransferase and HMG CoA reductase inhibitors and their use to treat cancer | |
AU721786B2 (en) | Cycloalkyl inhibitors of protein farnesyltransferase | |
US6737410B1 (en) | Inhibitors of protein farnesyl transferase | |
KR20000015892A (ko) | 단백질 파르네실 트랜스퍼라제의 억제제 | |
MXPA00009613A (en) | Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors | |
MXPA99001592A (es) | Inhibidores cicloalquilo de proteina farnesiltransferasa | |
MXPA00011113A (en) | Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |